ArticleNutrition research and practice2025
Anti-osteoarthritis effect of a standardized
Article in Nutrition research and practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- The Anti-Osteoarthritis Effect of Medicinal and Edible Homologous Bioactive Components and Chinese Medicinal and Health Food Varieties.Nutrients · 2026Review
- Article
- Therapeutic efficacy of Curcuma longa leaf extract in experimental models of arthritis.Inflammopharmacology · 2026Article
- Recent Advances in Therapeutic Approaches for Knee Osteoarthritis: a Narrative Review.Biomolecules & therapeutics · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUNDS/
objectivesThis study examined the anti-osteoarthritic effects of a MATERIALS/
methodsThe rats were divided into a normal control group (NC), OA control group (OC), OA +10, 20, 30, or 50 mg/kg body weight (BW)/day CLE-administered group (O+CL10, O+CL20, O+CL30, or O+CL50), and OA+150 mg/kg BW/day methyl sulfonyl methane (MSM, positive control)-administered group (O+M). The rats were given oral doses of CLE or MSM for 5 weeks, with an intra-articular injection of MIA into their knee joints on the 15th day to induce OA. Micro-computed tomography, histological examination, and immunofluorescence staining were performed on the knee joint. The inflammatory mediators, cytokines, and matrix metalloproteinase (MMP) mRNA expression were measured in the knee joint synovial fluid.
resultsThe OC group showed more severe knee joint swelling and subchondral bone erosion than the NC group, and aggrecan and type II collagen expression in the articular cartilage was reduced. The OC group exhibited lower mRNA expression of inflammatory mediators, cytokines, and MMPs than the NC group. In OA-induced rats, the oral administration of the CLE reduced knee swelling and cartilage degradation and increased aggrecan and type II collagen expression in the articular cartilage. CLE administration reduced the expression of inducible nitric oxide synthase, cyclooxygenase-2, 5-lipoxygenase, interleukin (IL)-1β, IL-6, tumor necrosis factor-α, MMP-2, MMP-3, MMP-9, and MMP-13 in the synovia of knee joints. In particular, these levels reached the same as the positive control group, the O+M group.
conclusionThe CLE had potent anti-OA effects in MIA-induced OA rats by suppressing the expression of inflammatory mediators, cytokines, and MMPs, alleviating cartilage degradation. Hence, the CLE is a potential functional food ingredient that can prevent and improve OA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.